SINT

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management characterized the second quarter as a fundamental transition from a research-focused entity to a commercially-driven biomaterials and medical technology platform. Revenue growth of 199% was primarily attributed to increased demand and improved pricing within the OEM industrial manufacturing business, which serves as the company's near-term commercial foundation. Gross margin expansion to approximately 62% was driven by a favorable sales mix and higher-margin OEM products, though management cautioned that these results stem from a small revenue base. The company is adopting a two-pronged value model: utilizing contract manufacturing for immediate operating leverage while leveraging proprietary silicon nitride for long-term strategic partnerships. The SiNAPTIC Foot & Ankle Wedge System achieved its first clinical use in March 2026, marking the company's move into active medical device commercialization. Operational focus has shifted toward converting a $3.2 million purchase order backlog into recognized revenue through disciplined manufacturing and quality control. Management acknowledged that the current cost structure remains high relative to revenue, necessitating a rigorous evaluation of staffing and project priorities to ensure commercial return. Revenue is projected to reach $900,000 to $1.1 million in Q3 2026 and $1 million to $1.3 million in Q4 2026, contingent on production timing and customer scheduling. Future revenue recognition for the $3.2 million in announced purchase orders is expected to extend into 2027, subject to manufacturing yields and customer acceptance. The commercial strategy for the SiNAPTIC wedge system will prioritize capital-efficient routes, such as distributor relationships, over building a large internal sales infrastructure. Management is actively pursuing OEM licensing and strategic partnerships to provide market access and development funding without internalizing all commercial capabilities. Liquidity remains a central concern, with management planning to seek additional equity or debt financing to address the 'substantial doubt' regarding the company's ability to continue as a going concern. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. A reallocation of approximately $700,000 in overhead costs from R&D to G&A reflects the company's shifting focus from technical development to general operations. Inventory increased to $2.3 million to support anticipated customer demand, creating a near-term working capital requirement that management must balance against cash reserves. The company engaged board member Chris Lyons and Southern Metrics to evaluate inbound strategic opportunities and commercial partnerships. Despite raising $5 million in gross proceeds during the quarter, the company reported a net loss of $2.7 million and maintains a going concern warning in its SEC filings.

This article first appeared on GuruFocus. Release Date: August 11, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Second-quarter revenue increased 199% year-over-year to $452,000, with product revenue up 347% to $447,000. Gross profit surged 388% to $278,000, and gross margin improved to approximately 62% from 38% a year ago. Received purchase orders from multiple contract manufacturing customers exceeding $3.2 million, providing commercial visibility into 2027. SINAPTIC Foot and Ankle Osteotomy Wedge System achieved FDA 510(k) clearance and first clinical use, with initial commercial revenue recognized. Completed financing transactions generating approximately $5 million in gross proceeds, including a private placement and ATM sales, with $5.1 million remaining ATM capacity. Substantial doubt remains regarding the company's ability to continue as a going concern, with only $3.6 million in cash at quarter end. Net loss widened to $2.7 million in Q2 2026, up from $2.3 million in the prior-year quarter. Operating expenses increased 16% to $3.2 million, driven by higher G&A and sales and marketing costs. Cash used in operating activities rose to $5.3 million in the first half of 2026, up from $3.7 million a year ago. Revenue guidance for Q3 and Q4 2026 is modest ($900K-$1.1M and $1M-$1.3M, respectively) and subject to significant uncertainty. Warning! GuruFocus has detected 7 Warning Signs with SINT. Is SINT fairly valued? Test your thesis with our free DCF calculator. Q: What were the key financial results for the second quarter of 2026, and what drove the improvements? A: (Eric Olson, CEO) Second-quarter revenue increased 199% year-over-year to $452,000, with product revenue up 347% to $447,000. Gross profit increased 388% to $278,000, and gross margins improved to approximately 62% from 38% a year ago. The improvements were driven by higher product sales, improved pricing on certain OEM products, a favorable sales mix, and early commercial sales of the SINAPTIC Osteotomy Foot and Ankle Wedge System. Q: Can you elaborate on the company's liquidity position and the going concern disclosure? A: (Eric Olson, CEO) On June 30, we had approximately $3.6 million in cash and cash equivalents and $4.8 million in stockholders' equity. We completed financing transactions generating approximately $5 million in gross proceeds during the quarter. However, substantial doubt remains regarding our ability to continue as a going concern, and we do not minimize that disclosure. Our responsibility is to increase revenue, manage operating and working capital requirements, pursue cost actions, and access capital prudently. Q: What is the status of the contract manufacturing business and the announced purchase orders? A: (Eric Olson, CEO) Product revenue growth was driven primarily by increased sales in our OEM industrial manufacturing business. In June, we announced purchase orders from multiple existing customers with an aggregate value exceeding $3.2 million. Production and shipment activities have begun and will continue into 2027. The milestones that matter are qualified production, manufacturing yield, quality release, on-time shipment, customer acceptance, recognized revenue, and repeat orders. We will distinguish clearly between order value and recognized revenue. Q: What are the company's revenue expectations for the remainder of 2026? A: (Kevin Trask, CFO) Based on current production schedules and customer requirements, we expect total revenue to be approximately $900,000 to $1.1 million in the third quarter and approximately $1 million to $1.3 million in the fourth quarter of 2026. These expectations are subject to significant uncertainty, particularly with respect to production timing, customer scheduling, and manufacturing execution. Q: How is the SINAPTIC Foot and Ankle Wedge System commercialization progressing? A: (Eric Olson, CEO) The system received FDA 510(k) clearance in late 2025, and the first wedges were used in a reconstructive procedure in March 2026, with initial commercial revenue recognized during our limited use review. We are focused on building adoption through surgeon education, channel development, and product availability. We are evaluating the most capital-efficient routes to market, including direct-to-surgeon engagement, distributor relationships, and broader strategic relationships. Q: Can you explain the changes in operating expenses, particularly the decline in R&D expense? A: (Kevin Trask, CFO) Total operating expenses increased 16% to $3.2 million. R&D expense decreased 54% to $573,000, primarily due to the reallocation of approximately $700,000 of overhead costs to general and administrative expense. G&A expense increased 64% to $2.3 million, reflecting higher headcount costs, non-cash stock-based compensation, and the overhead reallocation. Sales and marketing expense increased to $273,000 due to commercial headcount and launch-related activity for SINAPTIC. Q: What is the company's strategy for its proprietary silicon nitride medical platform? A: (Eric Olson, CEO) The business model is built around two complementary sources of value: contract manufacturing and OEM activities for near-term revenue, and the proprietary silicon nitride medical platform for differentiated products and potential OEM licensing, distribution, and strategic partnership opportunities. We are prioritizing programs based on time to revenue, required capital, regulatory pathways, and partner interest. We have engaged Board member Chris Lyons and his company, Southern Metrics, to help coordinate and evaluate inbound strategic opportunities. Q: What were the key balance sheet changes during the quarter? A: (Kevin Trask, CFO) Inventory increased to $2.3 million from $1 million at year-end, reflecting purchases and production activity to support anticipated customer demand. Net cash used in operating activities was $5.3 million for the first six months of 2026, compared with $3.7 million in the prior-year period. Net cash provided by financing activities was $4.8 million, including net proceeds from the June private placement and ATM sales. As of June 2026, we had approximately $5.1 million of remaining capacity under the ATM program. Q: How is management addressing the cost structure relative to the current revenue base? A: (Eric Olson, CEO) The current cost structure is highly relative to our revenue base, and we recognize that. Management is evaluating staffing, outside services, facilities, project priorities, and working capital through the lens of commercial return and strategic value. Our goal is not simply to reduce spending in isolation but to deploy capital where it can support revenue conversion, customer delivery, medical adoption, or transactions that improve the company's long-term position. Q: What are the company's priorities for the remainder of 2026? A: (Eric Olson, CEO) Our priorities are straightforward: first, execute the contract manufacturing orders already in hand with quality, timing, and working capital discipline; second, build a disciplined commercial foundation for the SINAPTIC wedge system; third, concentrate capital and management attention on programs and strategic relationships with a credible path to revenue or funded development; and fourth, continue aligning spending, staffing, inventory, and financing decisions with the milestones most likely to create value for shareholders. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

LivaNova (LIVN) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.05 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +16.67%. A quarter ago, it was expected that this medical technology company would post earnings of $0.85 per share when it actually produced earnings of $0.98, delivering a surprise of +15.29%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. LivaNova, which belongs to the Zacks Medical - Instruments industry, posted revenues of $390.6 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 2.90%. This compares to year-ago revenues of $352.5 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. LivaNova shares have added about 38.7% since the beginning of the year versus the S&P 500's gain of 13%. While LivaNova has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for LivaNova was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.06 on $380.05 million in revenues for the coming quarter and $4.24 on $1.5 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. SINTX TECHNOLOGIES, INC. (SINT), another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 11. This company is expected to post quarterly loss of $0.69 per share in its upcoming report, which represents a year-over-year change of +24.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. SINTX TECHNOLOGIES, INC.'s revenues are expected to be $0.4 million, up 166.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report LivaNova PLC (LIVN) : Free Stock Analysis Report SINTX TECHNOLOGIES, INC. (SINT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +33.33%. A quarter ago, it was expected that this regenerative medicine company would post earnings of $0.12 per share when it actually produced earnings of $0.07, delivering a surprise of -41.67%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. AxoGen, which belongs to the Zacks Medical - Instruments industry, posted revenues of $69.73 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 4.31%. This compares to year-ago revenues of $56.66 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. AxoGen shares have added about 25.7% since the beginning of the year versus the S&P 500's gain of 8.5%. While AxoGen has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for AxoGen was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.15 on $70.25 million in revenues for the coming quarter and $0.49 on $271.08 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, SINTX TECHNOLOGIES, INC. (SINT), is yet to report results for the quarter ended June 2026. The results are expected to be released on August 11. This company is expected to post quarterly loss of $0.69 per share in its upcoming report, which represents a year-over-year change of +24.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. SINTX TECHNOLOGIES, INC.'s revenues are expected to be $0.4 million, up 166.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AxoGen, Inc. (AXGN) : Free Stock Analysis Report SINTX TECHNOLOGIES, INC. (SINT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Company underscores its strengthened liquidity, cost reductions, and first revenue recorded from OsseoSculpt™ SALT LAKE CITY, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon-nitride–based medical technologies, today provided a business update reporting third quarter financial results in conjunction with the filing the Company’s Form 10-Q for the quarter ended September 30, 2025. During the third quarter and subsequent weeks, SINTX advanced a focused commercialization plan centered on infection-resistant silicon nitride devices and polymer composites, while tightening its operating footprint and strengthening its balance sheet. Business Highlights and Key Milestones FDA 510(k) Clearance: Received U.S. FDA clearance for the SINAPTIC® Foot & Ankle Osteotomy Wedge System, enabling SINTX’s commercial entry into reconstructive foot and ankle surgery in the U.S. Initial Product Revenue: Recorded first commercial revenue from the private-labeled orthobiologic product OsseoSculpt™, a companion biologic to the SINAPTIC wedge portfolio. Facility Optimization: Executed a sublease of the Armor facility, estimated to save up to approximately $950,000 in lease costs over the sublease term, further aligning operating resources with its medical device priorities. Broadened IP Portfolio: United States Patent and Trademark Office (USPTO) issued Notice of Allowance for patent application containing method claims covering the Company’s antipathogenic fabric technology. Strengthened Liquidity: Raised an additional $4.3 million in gross proceeds through warrant inducement and common stock warrant exercises. Third Quarter 2025 Financial Results: Cash and cash equivalents were $6.25 million on September 30, 2025, compared with $3.60 million on December 31, 2024, reflecting financing activity and disciplined working-capital management. Revenue of $0.2 million, a decrease as compared to $0.8 million in Q3 2024, primarily related to a reduction in grant revenue recognized compared to the prior period. Operating expenses of approximately $3.4 million, a decrease of 51% year-over-year. Operating loss of $3.4 million compared to $6.4 million in Q3 2024. Net loss of $3.5 million, representing a loss of $1.19 per fully diluted share, compared to net loss of $6.2 million representing a loss of $6.96 per fully diluted share in Q3 2024. Adjusted EBITDA loss of $2.3 million in Q3 2025 compared to $6.1 million in Q3 2024. “We have aligned SINTX squarely behind near-term commercial milestones with our advanced biomaterial products,” said Eric Olson, President and CEO of SINTX. “The 510(k) clearance for our SINAPTIC foot & ankle wedge system represents a pivotal milestone that validates our technology and establishes a scalable platform for future growth. We believe the decisive actions we have taken to monetize non-core assets, streamline facilities, and maintain prudent access to capital position the Company to execute this strategy effectively. The Company remains focused on advancing clinical leadership into sustainable product revenue opportunities, while building broader commercial utilization around silicon nitride’s unique clinical advantages.” Looking ahead, SINTX’s near-term priorities include: (i) preparing the SINAPTIC wedge system for launch; (ii) expanding clinical and key opinion leader (KOL) engagement in targeted surgical specialties; and (iii) leveraging its material science into adjacent indications — including polymer composites for 3D printed custom and patient specific implants — where silicon nitride’s antipathogenic and bone-affinity attributes can be most impactful. Management also intends to continue evaluating partnering, licensing, and capital formation options that we believe will accelerate market access and enhance shareholder value. For more information on SINTX Technologies or its materials platform, visit www.sintx.com. About SINTX Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. With thousands of medical devices implanted since 2008 and nearly two decades of peer-reviewed research, SINTX has established itself as a leader in high-performance biomaterials that enhance clinical outcomes and patient safety. Supported by a strong patent portfolio, U.S.-based manufacturing, and strategic industry partnerships, the company continues to expand its technology platform through innovation and market diversification, including the recently FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System for reconstructive surgery. Non-GAAP Financial Measures This press release contains adjusted EBITDA, which is a non-GAAP measure defined as net income excluding depreciation and amortization, income tax (benefit) expense, net interest (income) expense, stock-based compensation, change in fair value of contingent consideration, realized gain (loss) on investments, and (gain) loss on disposition of assets. The Company believes that adjusted EBITDA provides useful information to management and investors relating to its results of operations. The Company’s management uses this non-GAAP measure to compare the Company’s performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The Company believes that the use of adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company’s financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making. Adjusted EBITDA may differ from similarly titled measures used by other companies and should not be considered in isolation or as a substitute for measures of financial performance prepared in accordance with GAAP. Management uses Adjusted EBITDA solely as a supplemental tool to evaluate operating performance and for internal budgeting and planning purposes. Management does not consider the non-GAAP measure in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of the non-GAAP financial measure is that it excludes significant expenses that are required by GAAP to be recorded in the Company’s financial statements. In order to compensate for these limitations, management presents the non-GAAP financial measure together with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of the net income, the most comparable GAAP financial measure to adjusted EBITDA, is included at the end of this release. The Company urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the company’s business. Forward-Looking Statements Certain statements in this release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding SINTX Technologies’ commercialization plans and expected timing for the SINAPTIC Foot & Ankle Osteotomy Wedge System; potential surgeon adoption, clinical engagement, and commercial performance; anticipated benefits of facility optimization and financing activities; and the Company’s expectations regarding market opportunities, product development, and shareholder value creation. Forward-looking statements are based on current expectations, estimates, and projections about future events and are often identified by words such as “may,” “will,” “could,” “should,” “would,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “project,” “target,” “seek,” “continue,” and similar expressions. Plans and projections are subject to change based on market conditions, regulatory developments, and other factors beyond the Company’s control. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including, among others, risks related to commercialization execution, surgeon training and utilization, market acceptance, manufacturing scale-up, supply chain constraints, pricing and reimbursement, competitive products, intellectual property protection, integration of business operations, macroeconomic conditions, and reliance on third-party market estimates. FDA 510(k) clearance does not assure commercial success, and any discussion of potential infection-prevention or bone-affinity attributes of silicon nitride reflects materials-level research and is not part of the cleared indications for this product. Additional risks and uncertainties are described in SINTX’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, available at www.sec.gov. Forward-looking statements speak only as of the date of this release, and SINTX undertakes no obligation to update them, except as required by law. SINTX Contacts: Jack Perkins or Maria Hocut KCSA Strategic Communications [email protected] SINTX Technologies, Inc. 801.839.3502 [email protected] SINTX Technologies, Inc. Condensed Consolidated Balance Sheets - Unaudited (in thousands, except share and per share data) SINTX Technologies, Inc. Condensed Consolidated Statements of Operations - Unaudited (in thousands, except share and per share data) SINTX Technologies, Inc. GAAP AND NON-GAAP MEASURES (Unaudited) Reconciliation of net loss to adjusted EBITDA: